SIP
NBIX icon

Stoneridge Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History

Stoneridge Investment Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,670
Closed -$332K – 292
2017
Q1 		$332K Buy
+7,670
New +$329K 0.04% 244

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stoneridge Investment Partners's NBIX Position: Q2 2017 in Review

Stoneridge Investment Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2017, closing a stake of 7,670 shares — an estimated $332K sold.

Stoneridge Investment Partners first reported a position in NBIX in Q1 2017 and held it in 1 quarter. The position peaked at $332K in Q1 2017. 221 funds tracked by Wall St. Rank hold NBIX as of Q2 2017.

  • Stoneridge Investment Partners reported no remaining Neurocrine Biosciences position as of Q2 2017 after selling out during the quarter.
  • Stoneridge Investment Partners sold 7,670 Neurocrine Biosciences shares in Q2 2017, an estimated $332K.
  • Stoneridge Investment Partners first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 1 quarter.
  • Stoneridge Investment Partners's Neurocrine Biosciences position peaked at $332K in Q1 2017.
  • 221 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2017.

Based on Stoneridge Investment Partners's 13F filing for Q2 2017, filed 1 Aug 2017.